High expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Epithelial growth factor-like 7 (EGFL7) is a secretory protein with a well-characterized role in angiogenesis and the oncogenesis of certain solid tumors. Overexpression of is associated with adverse prognosis in patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, whether this association persists after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. To further clarify the prognostic role of , seventy-one AML patients with expression data who underwent allo-HSCT from The Cancer Genome Atlas database were included and divided into either or group based on the median expression level. Two groups had similar clinical and molecular characteristics except that the group had less frequent mutations (= .001). Kaplan-Meier survival curves showed that high expressers had shorter OS than the low expressers (= .040). Univariate analysis showed that high expression, and mutations were associated with short OS (all < .05). Multivariate analysis indicated that high expression, and mutations were independent risk factors for OS (all < .05). Collectively, our study suggested that , like the other widely-used risk stratification factors, could serve as a prognostic tool and therapeutic target in AML, even after allo-HCST.